Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

被引：0
|
作者：
Tereza Lanitis
Irina Proskorovsky
Apoorva Ambavane
Matthias Hunger
Ying Zheng
Murtuza Bharmal
Hemant Phatak
机构：
[1] Evidera,
[2] Evidera,undefined
[3] Mapi,undefined
[4] an ICON plc company,undefined
[5] EMD Serono Inc.,undefined
[6] Merck KGaA,undefined
来源：
Advances in Therapy | 2019年 / 36卷
关键词：
Avelumab; Extrapolation; Immuno-oncology; Landmark analyses; Merkel cell carcinoma; Overall survival; Post-progression survival; Standard parametric analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2327 / 2341
页数：14
相关论文
共 50 条
  • [21] Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe
    Fife, Kate
    Tetu, Pauline
    Prabhakaran, Jessica
    Lebbe, Celeste
    Grignani, Giovanni
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
    Sandra P. D’Angelo
    Matthias Hunger
    Andrew S. Brohl
    Paul Nghiem
    Shailender Bhatia
    Omid Hamid
    Janice M. Mehnert
    Patrick Terheyden
    Kent C. Shih
    Isaac Brownell
    Céleste Lebbé
    Karl D. Lewis
    Gerald P. Linette
    Michele Milella
    Michael Schlichting
    Meliessa H. Hennessy
    Murtuza Bharmal
    Cancer Immunology, Immunotherapy, 2019, 68 : 609 - 618
  • [23] Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
    D'Angelo, Sandra P.
    Hunger, Matthias
    Brohl, Andrew S.
    Nghiem, Paul
    Bhatia, Shailender
    Hamid, Omid
    Mehnert, Janice M.
    Terheyden, Patrick
    Shih, Kent C.
    Brownell, Isaac
    Lebbe, Celeste
    Lewis, Karl D.
    Linette, Gerald P.
    Milella, Michele
    Schlichting, Michael
    Hennessy, Meliessa H.
    Bharmal, Murtuza
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (04) : 609 - 618
  • [24] Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma
    Joseph, Jocelyn
    Zobniw, Chrystia
    Davis, Jennifer
    Anderson, Jaime
    Van Anh Trinh
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (09) : 928 - 935
  • [25] Avelumab-induced Pneumonitis in Metastatic Merkel Cell Carcinoma
    Morimoto, Toshiki
    Yamasaki, Kei
    Isoshima, Yu
    Yatera, Kazuhiro
    INTERNAL MEDICINE, 2022, 61 (17) : 2697 - 2698
  • [26] Avelumab: a new standard for treating metastatic Merkel cell carcinoma
    Baker, Mairead
    Cordes, Lisa
    Brownell, Isaac
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (04) : 319 - 326
  • [27] RETIFANLIMAB VS AVELUMAB IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA: A COST-UTILITY ANALYSIS IN ITALY
    Ghetti, G.
    Porta, C.
    Povero, M.
    Trimarchi, C.
    VALUE IN HEALTH, 2024, 27 (12) : S66 - S66
  • [28] COST-EFFECTIVENESS OF AVELUMAB IN THE TREATMENT OF PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN PORTUGAL
    Pinheiro, B.
    Silva Miguel, L.
    Alarcao, J.
    Palencia, R.
    Borges, M.
    VALUE IN HEALTH, 2020, 23 : S432 - S432
  • [29] Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up
    D'Angelo, S. P.
    Bhatia, S.
    Brohl, A. S.
    Hamid, O.
    Mehnert, J. M.
    Terheyden, P.
    Shih, K. C.
    Brownell, I
    Lebbe, C.
    Lewis, K. D.
    Linette, G. P.
    Milella, M.
    Xiong, H.
    Guezel, G.
    Nghiem, P. T.
    ESMO OPEN, 2021, 6 (06)
  • [30] Immunometabolic predictive factors in Merkel cell carcinoma (MCC) patients treated with avelumab.
    Badalamenti, Giuseppe
    Incorvaia, Lorena
    Algeri, Laura
    Carreca, Ignazio Ugo
    Brando, Chiara
    Madonia, Giorgio
    Peri, Marta
    Cucinella, Alessandra
    Perez, Alessandro
    Barraco, Nadia
    Russo, Tancredi Didier Bazan
    Pomi, Federica Li
    Carreca, Anna Paola
    Gristina, Valerio
    Galvano, Antonio
    Iovanna, Juan
    Fanale, Daniele
    Bazan, Viviana
    Russo, Antonio
    Carreca, Ignazio Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345